What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong year-over-year share gains.
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Overview
Francis Lo, Chief People Officer of Adaptive Biotechnologies (NASDAQ:ADPT), reported the sale of 39,741 shares of Common Stock for a transaction value of approximately $695,000, as disclosed in a SEC Form 4 filing.
Transaction and post-transaction values based on SEC Form 4 weighted average reported price ($17.49).
Details
* 1-year price change calculated as of June 4, 2026.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
